SLSU Readies Applications for Utility Models and Patents
Southern Leyte State University will soon be filing several utility model and patent applications with the Intellectual Property Office of the Philippines (IPOPhil) following a final consultation with experts from Samar State University’s (SSU) Innovation and Technology Support Office (ITSO) who were in SLSU-Sogod on June 14-15, 2016 to guide SLSU researchers on their final preparations prior to submission of their application to IPOPhil.
Present during the final meeting with SSU ITSO staff were faculty members from SLSU-Sogod, SLSU-San Juan and SLSU-Hinunangan. Of the 15 initial SLSU innovations presented in May 2016 during the Seminar-Workshop on Awareness in Copyright/Utility Model/Patent, Patent Search and Patent Drafting, 10 are being finalized for submission to IPOPhil. Within that mix are two patent applications coming SLSU-Sogod engineers – Jose Monteroso and Angel Sabusap, and eight utility model applications from faculty members in the fields of agriculture, computer studies and engineering.
“We had nine applications in 2012 and ten in 2013. In 2014, we had 12 applications and last year we had 15. For the approved applications, I think we already have 12 utility models,” said SSU ITSO Director Vivian Moya during the consultation with SLSU researchers on June 15.
The difference between a utility model and a patent is that while patents require novelty with at least 80% originality and potential for commercialization, utility models are rather an innovation of an existing technology, but must still possess marketability qualities.
Utility models take six months to process while patents take two years.
See also our related article SLSU Holds Seminar on Patents, Utility Models and Copyrights.
An exuberant engineering team pose for a photo at the RDE-Sogod office after submitting documents for two utility models and one patent application to SLSU ITSO Director Angel Sabusap.
SLSU faculty members with Samar State University’s Vivian Moya and Engr. Ryan Labutap during the June 14-15, 2016 consultations.